A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses

IBAÑEZ ANDRES; LORENA M. CORIA; CARABAJAL MARIANELA; DELPINO M. VICTORIA; RISSO GABRIELA; COBIELO PAULA; RINALDI J; BARRIONUEVO PAULA; BRUNO LAURA; FRANK FERNANDA; KINKLE S; GOLDBAUM FERNANDO; BRIONES GABRIEL; GIAMBARTOLOMEI GUILLERMO H; PASQUEVICH KARINA; CASSATARO JULIANA

JOURNAL OF CONTROLLED RELEASE

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2015

0168-3659

Wereporthere that a bacterial protease inhibitor from Brucella spp. called U-Omp19 behavesas an ideal constituent for a vaccine formulation against infectious diseases.Whenco-administered orally with an antigen (Ag), U-Omp19: i) can bypass the harshenvironment of the gastrointestinal tract by inhibiting stomach and intestineproteases and consequently increases the half-life of the co-administered Ag atimmune inductive sites: Peyer's patches and mesenteric lymph nodes while ii) itinduces the recruitment and activation of antigen presenting cells (APCs) andincreases the amount of intracellular Ag inside APCs. Therefore,mucosal as wellas systemic Ag-specific immune responses, antibodies, Th1, Th17 and CD8+ Tcells are enhanced when U-Omp19 is co-administered with the Ag orally. Finally,this bacterial protease inhibitor in an oral vaccine formulation confersmucosal protection and reduces parasite loads after oral challenge withvirulent Toxoplasma gondii.